{"id":31387,"date":"2025-03-25T16:38:03","date_gmt":"2025-03-25T11:08:03","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31387"},"modified":"2025-03-26T09:17:37","modified_gmt":"2025-03-26T03:47:37","slug":"pharma-news-for-telix-merck-alnylam","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam","title":{"rendered":"Clover\u2019s SCB-1019 RSV Revaccination Study Clears U.S. IND; FDA Approves AMVUTTRA for ATTR-CM CV Risk Reduction; Pembrolizumab Combo Greenlit for HER2+ Gastric\/GEJ Cancer; TREMFYA Becomes First IL-23 Inhibitor Approved for Crohn\u2019s; FDA OKs GOZELLIX for Prostate Cancer Imaging"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fc68e2575e7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fc68e2575e7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\/#Clovers_RSV_Vaccine_Candidate_SCB-1019_Gains_US_IND_Clearance_for_Revaccination_Study\" >Clover\u2019s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\/#FDA_Approves_AMVUTTRA_First_RNAi_to_Cut_Cardiovascular_Risks_in_ATTR-CM_Adults\" >FDA Approves AMVUTTRA, First RNAi to Cut Cardiovascular Risks in ATTR-CM Adults<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\/#FDA_Greenlights_Pembrolizumab_Combo_for_HER2-Positive_GastricGEJ_Adenocarcinoma\" >FDA Greenlights Pembrolizumab Combo for HER2-Positive Gastric\/GEJ Adenocarcinoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\/#FDA_Approves_TREMFYA_First_IL-23_Inhibitor_for_Crohns_Disease\" >FDA Approves TREMFYA, First IL-23 Inhibitor for Crohn\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\/#FDA_Approves_GOZELLIX_New_Imaging_Agent_for_Prostate_Cancer\" >FDA Approves GOZELLIX, New Imaging Agent for Prostate Cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-clover-s-rsv-vaccine-candidate-scb-1019-gains-u-s-ind-clearance-for-revaccination-study\"><span class=\"ez-toc-section\" id=\"Clovers_RSV_Vaccine_Candidate_SCB-1019_Gains_US_IND_Clearance_for_Revaccination_Study\"><\/span>Clover\u2019s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Clover Biopharmaceuticals, Ltd.<\/strong> has received <strong>FDA clearance <\/strong>for its <strong>Investigational New Drug (IND) <\/strong>application and has initiated a <strong>Phase I revaccination clinical trial for SCB-1019,<\/strong> its non-adjuvanted bivalent <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\">RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine<\/a>. The trial, now enrolling participants, aims to assess the safety, reactogenicity, and immunogenicity of SCB-1019, which is based on Clover\u2019s proprietary Trimer-Tag vaccine technology platform.<\/p>\n\n\n\n<p>The study includes up to 160 older adults (ages 60-85) who were previously vaccinated with GSK\u2019s RSV vaccine (AREXVY) at least two seasons ago. Participants will be randomized to receive either SCB-1019 as a heterologous revaccination dose, a homologous revaccination dose of AREXVY, or a saline placebo. This follows earlier Phase I data from October 2024, where SCB-1019 demonstrated a promising immunogenicity and tolerability profile in RSV vaccine-na\u00efve individuals when compared head-to-head with AREXVY. Clover also plans to advance SCB-1019 into a respiratory combination vaccine (RSV + hMPV \u00b1 PIV3) Phase I trial in 2025.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are pleased to announce the U.S. IND clearance and the initiation of our revaccination clinical trial, which highlights the differentiated global potential of Clover\u2019s RSV PreF vaccine (SCB-1019) utilizing our validated Trimer-Tag platform,\u201d said Joshua Liang, CEO and Board Director of Clover. He emphasized the need for improved RSV revaccination strategies, stating, \u201cWhile currently approved protein-based RSV vaccines are safe and effective for initial doses, critical gaps remain globally, including suboptimal boostability for revaccination and the inability to protect against related respiratory viruses such as hMPV and PIV3.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Looking ahead, Liang expressed optimism about SCB-1019\u2019s broader potential in respiratory protection. \u201cWe look forward to the trial results in an RSV revaccination setting and as part of a future respiratory combination vaccine,\u201d he said. With its ongoing trials, Clover aims to provide a next-generation RSV vaccine capable of addressing these global challenges while leveraging its Trimer-Tag technology for broader respiratory disease prevention.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-amvuttra-first-rnai-to-cut-cardiovascular-risks-in-attr-cm-adults\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AMVUTTRA_First_RNAi_to_Cut_Cardiovascular_Risks_in_ATTR-CM_Adults\"><\/span>FDA Approves AMVUTTRA, First RNAi to Cut Cardiovascular Risks in ATTR-CM Adults<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Alnylam Pharmaceutical<\/strong> has received <strong>FDA approval <\/strong>for a <strong>supplemental New Drug Application (sNDA) <\/strong>expanding the use of <strong>AMVUTTRA (vutrisiran)<\/strong> to include the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloidosis-market\">cardiomyopathy in wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)<\/a> in adults. This approval makes AMVUTTRA the first and only FDA-approved treatment for both ATTR-CM and <a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market\">hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN<\/a>). ATTR-CM is a progressive and fatal disease affecting an estimated 150K individuals in the U.S. and over 300K worldwide, with many patients remaining undiagnosed or experiencing disease progression despite existing treatments.<\/p>\n\n\n\n<p>The FDA\u2019s decision is based on results from the HELIOS-B Phase 3 trial, which demonstrated significant reductions in cardiovascular mortality and hospitalizations compared to placebo. The study showed a 28% reduction in all-cause mortality (ACM) and recurrent cardiovascular (CV) events over 36 months, with mortality reduction reaching 36% through 42 months in a secondary analysis. Patients treated with AMVUTTRA also maintained functional capacity and quality of life while showing early improvements in key biomarkers predictive of cardiovascular outcomes. These findings support AMVUTTRA\u2019s unique ability to target the root cause of ATTR-CM by reducing transthyretin (TTR) production through RNA interference (RNAi) therapy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of AMVUTTRA for ATTR-CM marks a pivotal advancement for patients, providing a new and clinically differentiated treatment option that has been shown to improve outcomes, including cardiovascular mortality, and reduce disease progression,\u201d said Yvonne Greenstreet, CEO of Alnylam. \u201cThis milestone reflects nearly two decades of collaboration with the ATTR amyloidosis community, and we remain committed to advancing treatment options so patients can live longer, healthier lives.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Ronald Witteles, M.D., a HELIOS-B investigator and Co-Director of the Stanford Amyloid Center, highlighted the significance of this approval. \u201cThe HELIOS-B trial enrolled a real-world patient population and demonstrated meaningful clinical benefits across cardiovascular outcomes and disease progression,\u201d he said. \u201cThis approval provides an opportunity to transform ATTR-CM treatment with a new mechanism of action that helps patients live longer and experience fewer hospitalizations.\u201d Muriel Finkel, President of the Amyloidosis Support Groups, also welcomed the approval, calling it \u201ca beacon of hope\u201d for patients and their families affected by this devastating disease.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-greenlights-pembrolizumab-combo-for-her2-positive-gastric-gej-adenocarcinoma\"><span class=\"ez-toc-section\" id=\"FDA_Greenlights_Pembrolizumab_Combo_for_HER2-Positive_GastricGEJ_Adenocarcinoma\"><\/span>FDA Greenlights Pembrolizumab Combo for HER2-Positive Gastric\/GEJ Adenocarcinoma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>FDA has granted traditional approval<\/strong> to <strong>pembrolizumab (KEYTRUDA)<\/strong> in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastroesophageal-adenocarcinoma-market\">metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/a> whose tumors express PD-L1 (CPS \u22651). This approval follows the drug\u2019s accelerated approval in May 2021 and is based on results from the KEYNOTE-811 trial, which demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) with pembrolizumab compared to placebo.<\/p>\n\n\n\n<p>The pivotal KEYNOTE-811 study was a multicenter, randomized, double-blind, placebo-controlled trial involving 698 patients, of whom 85% had PD-L1 CPS \u22651 tumors. Patients receiving pembrolizumab in combination with trastuzumab and chemotherapy experienced a median OS of 20.1 months compared to 15.7 months in the placebo arm (HR = 0.79). Median PFS was also significantly longer at 10.9 months versus 7.3 months (HR = 0.72). The combination therapy achieved a higher overall response rate (73% vs. 58%) and a longer median duration of response (11.3 months vs. 9.6 months). The safety profile of pembrolizumab in this setting was consistent with its known adverse reaction profile.<\/p>\n\n\n\n<p>This approval aligns with the FDA\u2019s Project FrontRunner initiative, which aims to bring effective cancer therapies into earlier treatment settings. The agency also granted orphan drug designation to pembrolizumab for this indication. The recommended dosing is 200 mg every three weeks or 400 mg every six weeks in combination with trastuzumab and chemotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-tremfya-first-il-23-inhibitor-for-crohn-s-disease\"><span class=\"ez-toc-section\" id=\"FDA_Approves_TREMFYA_First_IL-23_Inhibitor_for_Crohns_Disease\"><\/span>FDA Approves TREMFYA, First IL-23 Inhibitor for Crohn\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>FDA has approved TREMFYA (guselkumab)<\/strong> as the <strong><em>first and only <\/em><\/strong><strong>IL-23 inhibitor<\/strong> offering both subcutaneous and intravenous induction options for adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\">moderately to severely active Crohn\u2019s disease<\/a>. This approval expands TREMFYA\u2019s indications, building on its previous approval for <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\">ulcerative colitis<\/a> and reinforcing Johnson &amp; Johnson\u2019s commitment to addressing <a href=\"https:\/\/www.delveinsight.com\/report-store\/inflammatory-bowel-disease-market\">inflammatory bowel disease<\/a>.<\/p>\n\n\n\n<p>TREMFYA is a fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, a key driver of immune-mediated diseases such as CD. The approval is supported by robust Phase 3 clinical data, including the GRAVITI and GALAXI studies, which demonstrated the drug\u2019s superior efficacy compared to STELARA\u00ae in pooled endoscopic endpoints. The studies involved over 1,300 patients with moderately to severely active CD who had failed or were intolerant to conventional therapies or biologics. TREMFYA\u2019s ability to achieve endoscopic remission and sustained clinical response highlights its potential to transform CD treatment.<\/p>\n\n\n\n<p><strong>TREMFYA offers a flexible dosing regimen:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Induction:<\/strong> 400 mg SC at Weeks 0, 4, and 8 (administered as two consecutive 200 mg injections) or 200 mg IV infusions at Weeks 0, 4, and 8.<br><\/li>\n\n\n\n<li><strong>Maintenance:<\/strong> 100 mg SC at Week 16 and every 8 weeks thereafter, or 200 mg SC at Week 12 and every 4 weeks thereafter.<\/li>\n<\/ul>\n\n\n\n<p>With its first fully subcutaneous treatment regimen for CD, TREMFYA provides enhanced flexibility for both patients and providers. Additionally, Johnson &amp; Johnson offers the <strong>TREMFYA withMe<\/strong> patient support program, enabling eligible commercially insured patients to receive their first induction treatment within 24 hours.<\/p>\n\n\n\n<p>This approval marks TREMFYA\u2019s fourth U.S. indication since its initial approval for plaque psoriasis in 2017, followed by psoriatic arthritis in 2020 and UC in 2024. Johnson &amp; Johnson is also pursuing an sBLA for a SC induction regimen in UC, reinforcing its leadership in immune-mediated disease innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-gozellix-new-imaging-agent-for-prostate-cancer\"><span class=\"ez-toc-section\" id=\"FDA_Approves_GOZELLIX_New_Imaging_Agent_for_Prostate_Cancer\"><\/span>FDA Approves GOZELLIX, New Imaging Agent for Prostate Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has approved <strong>GOZELLIX (TLX007-CDx)<\/strong>, a next-generation <strong>PSMA-PET imaging agent<\/strong> developed by Telix Pharmaceuticals for <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\">prostate cancer<\/a>. This newly approved diagnostic tool, which uses gallium-68 (68Ga) gozetotide injection, is indicated for PSMA-positive lesions in men with suspected metastasis or recurrence based on elevated PSA levels. GOZELLIX builds upon Telix\u2019s ILLUCCIX, enhancing availability and efficiency in <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-diagnostics-market\">prostate cancer imaging<\/a>.<\/p>\n\n\n\n<p>GOZELLIX offers extended shelf life (up to six hours) and a broader distribution radius, addressing access challenges in PSMA-PET imaging. Its formulation allows for more scalable production, increasing efficiency and flexibility for scanning centers. This advancement ensures more American men\u2014especially in underserved regions\u2014gain access to high-accuracy PSMA imaging, improving diagnostic precision and treatment planning.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Kevin Richardson, CEO of Telix Precision Medicine, emphasized the significance of this approval, stating, \u201cSecuring FDA approval for GOZELLIX is a major win for prostate cancer patients, who gain enhanced access to state-of-the-art 68Ga PSMA-PET imaging.\u201d He highlighted Telix\u2019s dedication to continuous improvement, noting, \u201cWith the launch of GOZELLIX, our team is excited to be bringing the new generation of prostate cancer scanning to more American men.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Additionally, GOZELLIX\u2019s approval is expected to ease financial barriers, as it is eligible for full reimbursement, potentially eliminating or reducing patient co-insurance. The company believes this will drive greater adoption of precision medicine imaging in prostate cancer care. Richardson reaffirmed Telix\u2019s commitment to innovation, saying, \u201cTelix continues to invest in innovation across our portfolio, and GOZELLIX is a testament to this continuous improvement approach.\u201d<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Clover\u2019s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study Clover Biopharmaceuticals, Ltd. has received FDA clearance for its Investigational New Drug (IND) application and has initiated a Phase I revaccination clinical trial for SCB-1019, its non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine. The trial, now enrolling participants, aims to assess the [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31388,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16852,2077,204,704,21480,263,16269,327,2595,349,420,639,498,22317,5789,17615,1939],"industry":[17225],"therapeutic_areas":[17239,17238,17231],"class_list":["post-31387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amyloidosis","tag-crohns-disease","tag-delveinsight","tag-fda","tag-gastroesophageal-junction-adenocarcinoma","tag-genetic-disorders","tag-hereditary-transthyretin-amyloidosis-market","tag-infectious-diseases","tag-inflammatory-bowel-disease","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-prostate-cancer","tag-prostate-cancer-diagnostics","tag-recent-pharma-news","tag-respiratory-syncytial-virus","tag-transthyretin-amyloidosis","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-genetic-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Telix, \u200bMerck, Alnylam<\/title>\n<meta name=\"description\" content=\"Telix\u2019s SCB-1019, Alnylam\u2019s AMVUTTRA, Merck\u2019s pembrolizumab, Johnson &amp; Johnson\u2019s TREMFYA, Telix\u2019s GOZELLIX\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Telix, \u200bMerck, Alnylam\" \/>\n<meta property=\"og:description\" content=\"Telix\u2019s SCB-1019, Alnylam\u2019s AMVUTTRA, Merck\u2019s pembrolizumab, Johnson &amp; Johnson\u2019s TREMFYA, Telix\u2019s GOZELLIX\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T11:08:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T03:47:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Telix, \u200bMerck, Alnylam","description":"Telix\u2019s SCB-1019, Alnylam\u2019s AMVUTTRA, Merck\u2019s pembrolizumab, Johnson & Johnson\u2019s TREMFYA, Telix\u2019s GOZELLIX","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Telix, \u200bMerck, Alnylam","og_description":"Telix\u2019s SCB-1019, Alnylam\u2019s AMVUTTRA, Merck\u2019s pembrolizumab, Johnson & Johnson\u2019s TREMFYA, Telix\u2019s GOZELLIX","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-03-25T11:08:03+00:00","article_modified_time":"2025-03-26T03:47:37+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam","name":"Pharma News | Telix, \u200bMerck, Alnylam","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam.png","datePublished":"2025-03-25T11:08:03+00:00","dateModified":"2025-03-26T03:47:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Telix\u2019s SCB-1019, Alnylam\u2019s AMVUTTRA, Merck\u2019s pembrolizumab, Johnson & Johnson\u2019s TREMFYA, Telix\u2019s GOZELLIX","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-telix-merck-alnylam#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam.png","width":772,"height":482,"caption":"pharma-news-for-telix-\u200bmerck-alnylam"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/03\/25163730\/pharma-news-for-telix-%E2%80%8Bmerck-alnylam-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyloidosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gastroesophageal junction adenocarcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genetic Disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hereditary transthyretin amyloidosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infectious Diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inflammatory bowel disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Amyloidosis<\/span>","<span class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">gastroesophageal junction adenocarcinoma<\/span>","<span class=\"advgb-post-tax-term\">Genetic Disorders<\/span>","<span class=\"advgb-post-tax-term\">hereditary transthyretin amyloidosis market<\/span>","<span class=\"advgb-post-tax-term\">Infectious Diseases<\/span>","<span class=\"advgb-post-tax-term\">Inflammatory bowel disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/span>","<span class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Mar 25, 2025","modified":"Updated on Mar 26, 2025"},"absolute_dates_time":{"created":"Posted on Mar 25, 2025 4:38 pm","modified":"Updated on Mar 26, 2025 9:17 am"},"featured_img_caption":"pharma-news-for-telix-\u200bmerck-alnylam\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31387"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31387\/revisions"}],"predecessor-version":[{"id":31391,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31387\/revisions\/31391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31388"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31387"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31387"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}